Targeted Therapy Market Size, Share Analysis, Growth Trends and Forecast 2026-2033

Targeted Therapy Market Size

The Targeted Therapy Market reached US$ 88.28 billion in 2025 and is expected to reach US$ 147.16 billion by 2033, growing at a CAGR of 7.2% during the forecast period 2026-2033.

The targeted therapy market is experiencing significant growth driven by the rising R&D investments, regulatory approvals, and novel product launches. The innovations in targeted therapy are driven by the rising prevalence of cancer and the growing demand for targeted therapies. However, the high cost of treatment, patient adherence, and compliance issues can significantly hinder the targeted therapy adoption. The emerging markets, such as Asia-Pacific, Latin America, and Eastern Europe, provide an opportunity for market expansion in the forecast period.

Targeted Therapy Market Key Takeaways

• USD 147.16 billion is the 2033 market opportunity. The targeted therapy market reached USD 79.18 billion in 2024 and is projected to expand at a 7.2% CAGR during 2025-2033, supported by rising cancer incidence, R&D investment, regulatory approvals and novel product launches.
• North America remains the center of gravity. The region accounted for the largest 48.3% market share in 2024, supported by advanced healthcare infrastructure, strong pharmaceutical R&D, favorable reimbursement and the presence of major targeted therapy manufacturers.
• Cancer prevalence is the fundamental growth engine. Rising global cancer incidence is increasing demand for therapies that selectively target tumor biology. Global cancer cases are projected to rise from nearly 20 million in 2022 to 24.10 million by 2030, strengthening the long-term treatment opportunity.
• Monoclonal antibodies dominate targeted therapy. The segment held a 62.5% share in 2024, reflecting widespread use of antibody-based therapies targeting HER2, EGFR, VEGF and CD antigens across breast, colorectal, lung, leukemia and other cancers.
• HER2-targeted therapies remain commercially significant. Products including Perjeta, Kadcyla, Phesgo and Herceptin demonstrate the strong commercial position of HER2 inhibitors, particularly in breast cancer treatment.
• Precision oncology is becoming increasingly important. Targeted therapies are shifting cancer treatment away from broad cytotoxic approaches toward therapies designed around specific molecular receptors, mutations and tumor pathways, improving treatment precision and potentially reducing effects on healthy cells.
• Regulatory approvals are accelerating market expansion. Recent approvals such as EMRELIS for c-Met-overexpressing NSCLC, TIVDAK for advanced or recurrent cervical cancer, and Itovebi for PIK3CA-mutated breast cancer are expanding the addressable patient population and strengthening targeted therapy pipelines.
• High treatment costs remain a major adoption barrier. Expensive targeted therapies and the need for repeated administration can increase the financial burden on patients, insurers and healthcare systems, particularly in low- and middle-income markets.
• Emerging markets represent the next expansion opportunity. Asia-Pacific, Latin America and Eastern Europe provide significant growth potential as healthcare infrastructure, cancer diagnosis, treatment access and adoption of advanced oncology therapies continue to improve.

Targeted Therapy Scope

Targeted Therapy Market Executive Summary

                                                        For more details on this report – Request for Sample

Targeted Therapy Dynamics: Drivers & Restraints

The rising incidence and prevalence of cancer are driving the market growth

Targeted therapy has evolved as the most promising approach for the treatment of cancer. As the global burden of the disease grows, the demand for these advanced therapies is expected to grow. These targeted therapies are currently designed to treat various types of cancer, a condition with a substantially high number of cases worldwide. The incidence and prevalence of cancer are rising due to various factors, including the aging population, changes in lifestyle, environmental factors, etc.

As per the International Agency for Research on Cancer, globally, nearly 20 million incident cases were reported in 2022. In 2030, nearly 24.10 million cases and in 2040, nearly 29.90 million cases were expected. 

This alarming rise in cancer cases is driving demand for targeted therapies, which are increasingly seen as an effective alternative to traditional treatments like chemotherapy, radiation, and surgery.

High Cost of targeted therapies may restrain the market growth

Targeted therapies have evolved as a promising option for cancer, treating the one’s with were once highly mortal. However, these therapies are expensive, and their high cost can significantly hinder their adoption, especially in low to middle-income countries and among patients with partial or no insurance coverage. 

For instance, the most popular targeted therapy drug, trastuzumab, sold under the brand name Enhertu, is priced at US$ 3,142.90 for 1 powder for injection. This high cost not only places a significant burden on patients but also strains healthcare systems and insurance providers.

These targeted therapies need frequent administrations to patients to achieve the desired remission, which can further increase overall costs for patients. As a result, the affordability of these treatments may limit their widespread adoption, slow market penetration, and reduce access for patients who could benefit from these advanced therapies. Thus, the above factors could be limiting the global targeted therapy market's potential growth. 

Targeted Therapy Segment Analysis

The global targeted therapy market is segmented based on type, indication, route of administration, and region.

Monoclonal antibodies in the type segment accounted for 62.5% of the market share in 2024 in the global targeted therapy market

Monoclonal antibodies are the products designed to mimic the antibodies produced by the human body’s immune system. These agents are known to specifically bind to biological receptors and trigger the respective mechanisms. In cancer, these monoclonal antibodies act by binding to various surface receptors of cancerous cells and blocking specific molecules that are involved in tumor growth and survival, such as HER2, EGFR, VEGF, or CD antigens. Unlike traditional chemotherapy, which affects both healthy and cancerous cells, monoclonal antibodies offer a more targeted approach, allowing for increased precision and reduced side effects. 

Based on the receptor target, these monoclonal antibodies, which act as targeted therapeutics in cancers, are classified into VEGF Inhibitors, CD Antigen-Targeted mAbs, EGFR Inhibitors, HER2 Inhibitors, etc. These monoclonal antibodies are indicated in various cancers such as breast cancer, colorectal cancer, various leukemias, gynecological cancers, lung cancer, liver cancer, head and neck cancers, etc. 

Among these antibodies, HER2 inhibitors have gained huge popularity due to their targeted mechanism in breast cancer, which is one of the most prevalent cancers worldwide. These drugs include Trastuzumab (Herceptin),  Pertuzumab (Perjeta), Trastuzumab deruxtecan (Enhartu), Trastuzumab emtansine (Kadcyla), etc. These are among the top-selling targeted therapy drugs currently, and below are their sales values.

Targeted Therapy Geographical Analysis

North America dominated the targeted therapy market with the highest share of 48.3% in 2024

North America is the region with an advanced healthcare industry. The region's dominance in the targeted therapy is mainly attributable to a higher proportion of sales generated by key manufacturers from the region. For instance, F. Hoffmann-La Roche Ltd, a key player in the targeted therapy market, has generated 33.71% from the United States, from the sales of its HER2 inhibitors portfolio (total sales: US$ 9,928.20; US Sales: US$ 3,347.29)

Moreover, research activities related to cancer are higher in the region due to favorable funding and high investments, which help manufacturers develop and launch novel therapies. In addition, the favorable reimbursement scenario in the region makes the highly expensive drugs available at affordable prices to the patients, making them accessible to those in need. Also, due to stringent regulatory guidelines for product approval, the launch of target therapies in the U.S. initially will provide a positive nod for universal acceptance, hence, the majority of the product innovators focus on launching their product initially in this region. 

Targeted Therapy Major Players

The major players in the targeted therapy market are F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc., AstraZeneca, Eisai Inc., Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company., Incyte, Eli Lilly and Company, and Exelixis, Inc., among others.

Targeted Therapy Recent Development

• July 2026 – FDA approves zidesamtinib for ROS1-positive lung cancer
  The U.S. FDA approved zidesamtinib (Jideytro) for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer previously treated with at least one ROS1 tyrosine kinase inhibitor (TKI), expanding biomarker-driven targeted treatment options.
• July 2026 – FDA expands targeted treatment options for HR-positive breast cancer
  The FDA approved gedatolisib in combination with fulvestrant, with or without palbociclib, for certain adults with HR-positive, HER2-negative advanced or metastatic breast cancer, reinforcing the role of pathway-directed therapies in precision oncology.
• June 2026 – Gilead expands targeted ADC-based treatment for triple-negative breast cancer
  The FDA approved sacituzumab govitecan (Trodelvy) as a first-line treatment option for certain adults with unresectable locally advanced or metastatic triple-negative breast cancer, including use in combination with pembrolizumab for PD-L1-positive disease.
• May 2026 – FDA approves first-in-class PROTAC targeted therapy
  The FDA approved vepdegestrant (Veppanu), a heterobifunctional protein degrader, for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, marking a major advancement for targeted protein degradation in oncology.
• May 2026 – Targeted therapy advances for rare NRG1 fusion-positive cancer
  The FDA approved zenocutuzumab (Bizengri) for adults with advanced or metastatic cholangiocarcinoma harboring an NRG1 gene fusion after prior systemic therapy, highlighting increasing commercialization of highly biomarker-specific therapies for rare cancers.
• May 2026 – BCL-2 targeted therapy gains accelerated FDA approval
  The FDA granted accelerated approval to sonrotoclax (Beqalzi), a BCL-2 inhibitor, for adults with relapsed or refractory mantle cell lymphoma following at least two systemic treatment lines, including a BTK inhibitor.
• February 2026 – HER2-targeted therapy expands in non-small cell lung cancer
  The FDA granted accelerated approval to zongertinib (Hernexeos) for unresectable or metastatic non-squamous NSCLC with HER2/ERBB2 tyrosine kinase domain activating mutations, strengthening mutation-directed treatment options in lung cancer.
• February 2026 – BRAF-targeted colorectal cancer therapy receives traditional approval
  The FDA granted traditional approval to encorafenib in combination with cetuximab and fluorouracil-based chemotherapy for metastatic colorectal cancer carrying a BRAF V600E mutation, reinforcing biomarker-guided combination therapy.

Key Procurement Priorities and Buyer Evaluation Criteria

• The procurement decision-making process in the targeted therapy market is being influenced by the growing adoption of precision medicine, rising cancer incidence, advances in molecular diagnostics, increasing use of biomarker-driven treatments, and demand for therapies that deliver improved clinical outcomes with fewer off-target effects. Buyers are increasingly evaluating targeted therapy solutions based on therapeutic efficacy, patient response rates, safety profiles, biomarker specificity, and compatibility with personalized treatment strategies.
• Buyers evaluate factors such as clinical efficacy, progression-free survival, overall survival, response durability, adverse-event profiles, mechanism of action, biomarker specificity, and regulatory approvals when assessing targeted therapy products for oncology and other therapeutic applications.
• The buyer also considers companion diagnostic availability, molecular profiling capabilities, patient selection criteria, treatment-line applicability, combination therapy potential, dosing convenience, and compatibility with existing diagnostic and clinical workflows while selecting targeted therapy providers and technology partners.
• Procurement decisions are further shaped by commercialization and accessibility considerations, with buyers evaluating treatment cost, reimbursement coverage, manufacturing scalability, supply reliability, regulatory compliance, intellectual property protection, and geographic availability as healthcare providers and pharmaceutical companies seek effective and economically sustainable targeted treatment options.

Why Choose DataM?

• Technological Innovations: Explores advancements in targeted therapy technologies, including monoclonal antibodies, antibody-drug conjugates (ADCs), small-molecule inhibitors, kinase inhibitors, immune-targeted therapies, and biomarker-guided treatment approaches, highlighting innovations that improve therapeutic precision, treatment efficacy, and patient outcomes.
• Product Performance & Market Positioning: Evaluates targeted therapy products based on critical parameters such as clinical efficacy, response rates, safety and tolerability, biomarker specificity, treatment durability, mechanism of action, combination potential, and regulatory status, highlighting how leading pharmaceutical companies differentiate their therapies across major disease areas.
• Real-World Evidence: Highlights the adoption of targeted therapies across oncology and other precision medicine applications, demonstrating their impact on patient selection, treatment response, disease management, survival outcomes, and personalized care pathways across hospitals, specialty clinics, and research institutions.
• Market Updates & Industry Changes: Tracks key developments such as regulatory approvals, clinical trial results, drug launches, companion diagnostic advancements, strategic collaborations, licensing agreements, acquisitions, and investments in precision medicine across North America, Europe, Asia-Pacific, and other emerging markets.
• Competitive Strategies: Analyzes how leading pharmaceutical and biotechnology companies expand their targeted therapy portfolios through R&D investments, clinical development, strategic partnerships, mergers and acquisitions, licensing agreements, companion diagnostic collaborations, and expansion into emerging therapeutic indications.
• Pricing & Market Access: Explains pricing variations based on therapy type, treatment indication, molecular target, development complexity, manufacturing requirements, treatment duration, and patient population, while assessing market access through hospitals, specialty pharmacies, oncology centers, healthcare providers, and pharmaceutical distribution networks.
• Market Entry & Expansion: Identifies growth opportunities driven by increasing cancer prevalence, expanding biomarker testing, rising precision medicine adoption, advancements in molecular diagnostics, growing clinical trial activity, and increasing pharmaceutical investment in targeted therapeutics, while outlining strategies such as regional expansion, localized clinical development, companion diagnostic partnerships, and differentiated therapy portfolios.

Target Audience

• Pharmaceutical & Biotechnology Companies
• Targeted Therapy Drug Manufacturers
• Oncology Drug Developers
• Precision Medicine Companies
• Biopharmaceutical R&D Organizations
• Hospitals & Cancer Treatment Centers
• Specialty Clinics & Healthcare Providers
• Companion Diagnostic Companies
• Molecular Diagnostics & Biomarker Testing Providers
• Contract Research Organizations (CROs)
• Contract Development & Manufacturing Organizations (CDMOs)
• Healthcare Investors & Venture Capital Firms
• Government & Regulatory Organizations
• Healthcare Distributors & Specialty Pharmacies